论文部分内容阅读
目的观察依达拉奉联合尼莫地平治疗高血压脑出血的效果及安全性。方法将90例高血压脑出血患者随机分为观察组和对照组各45例,对照组采取常规治疗,观察组在对照组治疗基础上给予依达拉奉联合尼莫地平治疗,对比2组患者血肿体积、水肿体积及并发症发生率。结果观察组高血压脑出血患者血肿体积及水肿体积均小于对照组,并发症的总发生率明显低于对照组,差异均有统计学意义(P<0.05)。结论采用依达拉奉联合尼莫地平治疗高血压脑出血患者,能够有效减小患者血肿及水肿体积,且安全性较高,值得在临床上推广应用。
Objective To observe the efficacy and safety of edaravone combined with nimodipine in the treatment of hypertensive intracerebral hemorrhage. Methods Ninety patients with hypertensive intracerebral hemorrhage were randomly divided into observation group and control group, 45 cases in each group. The control group received routine treatment. The observation group was treated with edaravone combined with nimodipine on the basis of the control group. Hematoma volume, edema volume and complication rate. Results The hematoma volume and edema volume of patients with hypertensive intracerebral hemorrhage in the observation group were all less than those in the control group. The overall incidence of complications was significantly lower than that of the control group (P <0.05). Conclusion Edaravone combined with nimodipine in patients with hypertensive intracerebral hemorrhage can effectively reduce the volume of hematoma and edema in patients with high safety and is worth popularizing in clinic.